

APLUSA BREAKFAST BRIEFING

A multi-client event gathering leading pharmaceutical companies and leading Key Opinion Leaders in obesity care.

- Held in Paris at Maison de la Recherche (*House of Research*)
- 8 leading pharmaceutical companies participated
- A multidisciplinary panel including a gastroenterologist, a GP, a pharmacist, an endocrinologist, and a patient advocacy leader.
- Focus: Comparing experiences and considering future challenges together, one year after the introduction of GLP-1 onto the market.



5 KEY LEARNINGS

1. A major shift in the healthcare professional–patient relationship

Healthcare professionals report a sharp increase in patient demand for obesity treatments, heavily influenced by media, peers, and social networks. This is transforming daily practice and creating pressure that sometimes clashes with clinical judgment.

2. Treatments seen as revolutionary, but still hard to access

GLP-1 analogs (Ozempic, Wegovy, Mounjaro, etc.) are considered therapeutic breakthroughs. However, due to stock shortages, prescribing restrictions, and administrative burdens, access remains limited, fueling frustration and inequities in care.

3. Care pathways remain unclear and unequal

Coordination between hospital and community care is lacking. The role of Obesity Specialized Centers (CSOs) is poorly defined, and professionals call for stronger territorial organization (local care networks, early detection, multidisciplinary approaches).

5 KEY LEARNINGS

4. Obesity must be officially recognized as a chronic disease

Professionals are advocating for long-term condition (LTC) recognition of obesity to improve reimbursement and legitimacy. They also call for stronger initial and ongoing training, and funding for longer consultations tailored to this complex condition.

5. Urgent need for structured partnerships

Pharma companies are expected to go beyond the product: providing clear, patient-friendly information, helping fight stigma, and contributing robust clinical evidence to support medical decisions and policy-level engagement.




WHAT'S NEXT?

NOW AVAILABLE – Discover our latest study on obesity care one year after the arrival of anti-obesity treatments, through the lens of eligible patients.



Review of obesity management since the
launch of anti-obesity treatments
Perspectives from eligible individuals



CONTACT US!

Book a meeting with our team to explore the full insights!



Manuel GUZMAN MARTIN

Vice President Client Engagement
m.guzmanmartin@aplusaresearch.com



Rose-Marie CARNEIRO

Vice President Client Engagement
Consumer Health
rm.carneiro@aplusaresearch.com



Justin FRANÇOIS

Key Account Director
j.francois@aplusaresearch.com



Sophie PENVERN

Research Director,
Consumer Health
s.penvern@aplusaresearch.com



APLUSA is ISO certified for market research, opinion and social research, data analytics, and strategic and tactical consulting dedicated to healthcare markets worldwide, in compliance with applicable regulations, to improve the reliability of our customers' decisions and contribute to better patient care.



www.aplusaresearch.com

Lyon

222 cours Lafayette
69003 Lyon
France
+33 (0) 478 622 323

Los Angeles

4695 MacArthur Court, 11th Floor
Newport Beach, California, 92660
United States

London

156 Blackfriars Road
London SE1 8EN,
United Kingdom
+44 20 7073 2666

Madrid

Calle de Méndez Álvaro, 20,
Arganzuela, 28045 Madrid,
Spain

New York Metro

445 Park Avenue, 9th Floor
New York, NY 10022
United States

Paris

159 rue Gallieni
92641 Boulogne Cedex
France
+33 (0) 146 035 452